NASDAQ · Biotechnology

Adaptimmune Therapeutics plc (ADAP) Stock

$0.05 -3.00% NASDAQ: ADAP Healthcare

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom.

Valuation

MetricValue
Price$0.05
Market Cap$75.16M
P/E Ratio-0.16
P/B Ratio-0.18
P/S Ratio3.59
EPS (TTM)$-0.28
52-Week High$0.86
52-Week Low$0.02
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE143.79%
ROA-59.65%
ROCE-96.08%
Gross Margin83.88%
Operating Margin-362.66%
Net Margin-371.74%
Debt/Equity-0.69
Current Ratio1.52

Annual Financials (USD)

Metric20202021202220232024
Revenue$4.0M$6.0M$27.0M$60.0M$178.0M
Operating Profit$-133.0M$-162.0M$-164.0M$-138.0M$-69.0M
Net Profit$-130.0M$-158.0M$-165.0M$-114.0M$-71.0M
EPS$-0.90$-1.02$-1.02$-0.57$-0.28
Op Margin-3370.5%-2638.6%-604.0%-229.0%-38.6%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$451.0M$470.0M$329.0M$283.0M$246.0M
Total Liabilities$110.0M$264.0M$247.0M$243.0M$234.0M
Cash$57.0M$150.0M$108.0M$144.0M$91.0M
Borrowings$24.0M$25.0M$23.0M$25.0M$74.0M

Latest News

Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In Simply Wall St. · Jul 24, 2026 Adaptive Biotechnologies (ADPT) Stock May Be 22% Undervalued As Growth Hopes Build Simply Wall St. · Jul 24, 2026 Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks · Jul 23, 2026 Will Earnings Estimate Upgrades and a Smaller Projected Loss Change Adaptive Biotechnologies' (ADPT) Narrative? Simply Wall St. · Jul 23, 2026 Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks · Jul 22, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-54.0M$11.0M$-142.0M$-141.0M$-73.0M
Investing Cash Flow$-282.0M$67.0M$59.0M$172.0M$-62.0M
Financing Cash Flow$6.0M$1.0M$0$0$0
Net Cash Flow$7.0M$90.0M$-42.0M$37.0M$-54.0M
Free Cash Flow$-56.0M$2.0M$-172.0M$-146.0M$-76.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.42
FCF Yield-134.98%
Quick Ratio1.29
Interest Coverage-26.74
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company's pipeline features several key candidates: ADP-A2M4 is in advanced clinical development, with Phase II trials underway for synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1), as well as for head and neck cancer (SPEARHEAD-2). Additionally, it is undergoing Phase I assessment for a wide range of cancers, including urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, and MRCLS. ADP-A2AFP is currently in Phase I clinical trials for hepatocellular carcinoma. ADP-A2M4CD8, which utilizes SPEAR T-cells, is also in Phase I trials for treating lung, gastroesophageal, head and neck, ovarian, and bladder cancers. Adaptimmune has established a diverse portfolio of strategic collaborations, including a licensing and partnership agreement with GSK, and third-party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and the National Center for Cancer Immune Therapy in Denmark. Further alliances include a strategic agreement with the MD Anderson Cancer Center and a co-development and co-commercialization agreement with Universal Cells, Inc. A significant strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd focuses on advancing personalized allogeneic T-cell therapies using aß T-cell receptors. Founded in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.

Adaptimmune Therapeutics plc is headquartered in GB.

Adaptimmune Therapeutics plc (ADAP) stock trades at $0.05 with a market capitalization of $75.16M. The stock is valued at a price-to-earnings (P/E) ratio of -0.16, price-to-book of -0.18, price-to-sales of 3.59. Over the past 52 weeks the stock has ranged between $0.02 and $0.86, and currently trades 94.2% below its 52-week high.

On profitability, Adaptimmune Therapeutics plc generates a return on equity (ROE) of 143.79% — well above the market average, a sign of a high-quality business, return on capital employed of -96.08%, an operating margin of -362.66%, a net profit margin of -371.74%.

Official website: www.adaptimmune.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides